ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Food Hypersensitivity
Hypersensitivity
Pruritus
Psoriasis

Eczema trials near Berlin, BE, DEU:

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (ADhope)

The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adu...

Active, not recruiting
Eczema
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Almirall
Almirall

Berlin, Germany and 32 other locations

The purpose of this study is to assess the safety, tolerability, drug levels, drug effects, and impact on disease severity of BMS-986326 in participa...

Active, not recruiting
Dermatitis, Atopic
Other: Placebo
Drug: BMS-986326

Phase 1

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, BE, Germany and 13 other locations

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Active, not recruiting
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

Phase 3

Incyte
Incyte

Berlin, Germany and 96 other locations

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have...

Active, not recruiting
Dermatitis, Atopic
Drug: GSK1070806

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Berlin, Germany and 58 other locations

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK10...

Active, not recruiting
Dermatitis, Atopic
Drug: GSK1070806
Drug: Placebo

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Berlin, Germany and 92 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Berlin, Germany and 536 other locations

The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with mod...

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Almirall
Almirall

Berlin, Germany and 31 other locations

In this study, it will be investigated if symptoms of atopic dermatitis of children with high familial risk will be delayed beyond the 6th or even 12...

Enrolling
Atopic Dermatitis
Infant, Newborn
Drug: SanaCutan Basiscreme

Phase 3

InfectoPharm

Berlin, Germany and 9 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Berlin, Germany and 536 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Mahlow, Germany and 194 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems